Friday, 16 April 2010

AMPYRA is a new therapy, the first ever with an indication to improve walking in MS

From Marketwatch:

Responders to AMPYRA Treatment Showed Improvement in Average Walking Speed Compared to their Average Baseline for Up to 2.5 Years in Open-Label Studies.

http://www.marketwatch.com/story/acorda-therapeutics-announces-data-on-ampyratm-dalfampridine-presented-at-american-academy-of-neurology-meeting-2010-04-13?reflink=MW_news_stmp